ESR1 and breast cancer: In ER-positive luminal-like breast cancer cells, EZH2 also acts as an activator independently of its SET domain through association with ER and WNT signaling components TCF/β-catenin to activate ER target genes such as c-myc and cyclin D1 [20] (Fig.2C, middle left).